Amlodipine for hand weakness in myotonic dystrophy type 1
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study tests whether the medication amlodipine can help improve symptoms of myotonic dystrophy type 1, particularly hand weakness and slow hand opening. Amlodipine is already used for blood pressure, but it may also affect the muscle problems in DM1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a confirmed diagnosis of myotonic dystrophy type 1 through genetic testing.
- Your hand grip strength is less than half of what is expected for your age, height, and sex.
- It takes you 4 seconds or longer to fully open one hand.
- You can walk 10 meters (about 30 feet) on your own.
- You are willing to stop taking any muscle-relaxing medications (anti-myotonia drugs) at least 2 weeks before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called PGN-EDODM1 for people with myotonic dystrophy type 1 (DM1). The goal is to see if it can help reduce symptoms like muscle stiffness (myotonia).
This trial tests an experimental drug called ATX-01 for people with myotonic dystrophy type 1 (DM1), a condition that causes muscle weakness and stiffness. The study aims to see if ATX-01 can help reduce symptoms like muscle stiffness (myotonia) and improve daily function.
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
This study measures physical and lab “health markers” in people with myotonic dystrophy type 1 (DM1) to better understand how the disease changes over time. Some participants may also have a muscle biopsy to study tissue differences.
This study follows people with myotonic dystrophy type 1 (DM1) over time to learn more about how the disease progresses. It collects health information and samples to help improve care.
This trial is testing a new drug called SRP-1003 for people with myotonic dystrophy type 1 (DM1) who developed symptoms after age 12. The goal is to see if it can reduce muscle problems like myotonia (difficulty relaxing muscles) and improve daily function.
Hear when a new Myotonic Dystrophy 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.